Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects

In-/off-label use of biologic therapy in systemic lupus erythematosus

(2014) Mariele Gatto et al.   BMC Medicine

Development and validation of an LC–MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target

(2014) Chao Gong et al.   Bioanalysis

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release

(2013) David Eastwood et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus

(2013) Nien Yee Kow et al.   Clinical & Developmental Immunology

A Monovalent Anti-Human CD28 Domain Antibody Antagonist: Preclinical Efficacy and Safety

(2013) S. J. Suchard et al.   JOURNAL OF IMMUNOLOGY

Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells

(2010) D Eastwood et al.   BRITISH JOURNAL OF PHARMACOLOGY

Increased CD28 serum levels are not associated with specific clinical activity in systemic lupus erythematosus

(2010) Aniel J. L. Brambila-Tapia et al.   RHEUMATOLOGY INTERNATIONAL

Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus

(2009) Elizabeth C. Jury et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The clinical utility of inhibiting CD28-mediated costimulation

(2009) Peter S. Linsley et al.   IMMUNOLOGICAL REVIEWS

Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

(2009) G. B. Appel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

CD8+CD28−, suppressive T cells in systemic lupus erythematosus

(2008) A Tulunay et al.   LUPUS